pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 20·1 min read
save

Endpoints News celebrates ten years of bootstrapped growth and a 50/50 founder partnership

Jun 20, 2026·read at Endpoints ↗Positive

John Carroll and Arsalan Arif launched Endpoints News a decade ago with no seed funding or investors, describing themselves as completely broke. They built the news service from scratch, relying on their own resources and early sales efforts at industry events.

Against typical advice, the two founders chose to split ownership evenly at 50/50. They said this unusual arrangement could have caused conflict, but it instead created a strong bond that proved essential as the business grew.

The partnership helped Endpoints News become profitable from its first day and sustain operations without external capital. Today the company operates from a London boardroom and has earned a feature in the Financial Times, marking a rare success story for a fully bootstrapped media venture.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Endpoints News History: 10 Years, Bootstrap to FT”

read at Endpoints ↗
971 words · retrieved Jun 20
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.2Sionna Therapeutics, Inc.
topics
Rare Disease2

related stories

  • Aug 25J&J’s Imaavy wins label expansion; Two approvals in JapanEndpoints
  • Aug 13'Incorrect and misleading' data prompted decision to pull Tavneos in EuropeEndpoints
  • Aug 10STAT+: Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trialSTAT
  • Jul 22Mentari adds $200M to migraine mission; Royalty's latest ATTR-CM dealEndpoints
  • Jun 15FDA plans to keep Makary priorities on trials, China, deputy saysEndpoints